INTREPID Alliance Antiviral Landscape: Overview of 13 Priority Viral Families*

As of December 18, 2024, for the 13 Viral Families with Greatest Risk of Pandemic Potential, Clinical Phase & Approved Antiviral Compounds Fall Into 9 of 13 and Preclinical Into 7 of 13 Viral Families

Primarily Respiratory Transmission

	Disease Indication (n)**	
Pillar	Preclinical (103)	Clinical (39)
Adenoviridae	X	• HuAdeno A-G (1)
Coronaviridae	• COVID-19 (74) • MERS-CoV (5) • SARS-CoV-1 (5) • Seasonal CoV (1)	• COVID-19 (25)
Orthomyxoviridae	• Influenza (12)	• Influenza (10)
Paramyxoviridae	• Hendra virus (1) • Measles (1) • Nipah virus (3) • Parainfluenza (1)	X
Picornaviridae	X	• Polio (2) • Rhinovirus (1)

X = absence of preclinical or clinical phase antivirals

Primarily Contact/Vector-Mediated Transmission

	Disease Indication (n)**	
Pillar	Preclinical (22)	Clinical (13)
Arenaviridae	• Junin virus (1) • Lassa fever (1)	• Lassa fever (3) • Chapare hem. fever (1)
Filoviridae	X	• Ebola (2)
Flaviviridae	• Dengue (5) • West Nile (1) • Yellow fever (1) • Zika (2)	• Dengue (3)
Hantaviridae	X	X
Nairoviridae	X	• Crimean Congo hem. fever (2)
Peribunyaviridae	X	X
Poxviridae	• Mpox (8)	• Mpox (2)
Togaviridae	• Chikungunya (3)	X

*As of December 18, 2024; **Number of compounds in ongoing development.

Preclinical Non-COVID-19 Indications

Preclinical Compound/Indications by Stage of Preclinical Development (Non-COVID-19; N=73)*



- Compound/Indications span the various stages of preclinical development.

*As of December 18, 2024.

INTREPID ALLIANCE

Preclinical Compound/Indications by Viral Family (Non-COVID-19; N=73)*



- Ten of the 13 viral families with pandemic potential have preclinical compound/indications.
  - *Orthomyxoviridae* has the most compounds and is focused on Influenza.

*As of December 18, 2024.

INTREPID ALLIANCE

Preclinical Compound/Indications by Stage of Preclinical Development and Viral Family (Non-COVID-19; N=73)*



- Compound/Indications span the various stages of preclinical development.
  - *Orthomyxoviridae* (Influenza) has the most compound/indications.

*As of December 18, 2024.

INTREPID ALLIANCE

Preclinical Compound/Indications by Viral Family and Stage of Preclinical Development (Non-COVID-19; N=73)*



- Compound/Indications span the various stages of preclinical development.
- The highest activity (12/51, 23.5%) is focused on *Orthomyxoviridae* (Influenza).

*As of December 18, 2024.

INTREPID ALLIANCE

Preclinical Compound/Indications by Viral Disease and Stage of Preclinical Development (Non-COVID-19; N=73)*



- Compound/Indications span the various stages of preclinical development.
- Most are focused on Influenza.

*As of December 18, 2024.

INTREPID ALLIANCE

Preclinical Compound/Indications by Stage of Preclinical Development and Viral Disease (Non-COVID-19; N=73)*



- Compound/Indications span the various stages of preclinical development.
- Most are focused on Influenza.

*As of December 18, 2024.

INTREPID ALLIANCE

Preclinical COVID-19 Indications

COVID-19 Compounds by Stage of Preclinical Development (N=75)*



*As of December 18, 2024.

INTREPID ALLIANCE

Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared for future pandemics.

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm's length from commercial influence of our member companies. See criteria listed in the report "Antiviral Clinical Development Landscape and Promising Clinical Compounds." The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria. "Promising" is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.